|
| Status |
Public on Jun 12, 2018 |
| Title |
Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The objective of this experiment was to determine the affect of H3B-5942 treatment on global gene expression in an estrogen-deprived setting (agonist mode) and to compare to treatment with a saturated analog of H3B-5942, GDC-0810, and standard of care agents tamoxifen and fulvestrant.
|
| |
|
| Overall design |
7 conditions were assessed (H3B-5924, H3B-9224, E2, fulvestrant, tamoxifen, GDC-810, and DMSO as negative control). Compounds were added at 2 concentrations (3nM and 30nM). Two samples of each condition were collected.
|
| |
|
| Contributor(s) |
Puyang X, Furman C, Wu ZJ |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jun 11, 2018 |
| Last update date |
Mar 21, 2019 |
| Contact name |
Zhenhua Wu |
| E-mail(s) |
zhenhuawu75@gmail.com
|
| Phone |
6179592279
|
| Organization name |
H3 Biomedicine
|
| Street address |
300 Technology Square floor 5
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (26)
|
|
| This SubSeries is part of SuperSeries: |
| GSE115611 |
Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer. |
|
| Relations |
| BioProject |
PRJNA475565 |
| SRA |
SRP150241 |
Less...
More...